A new microbiome diagnostic test providing rapid testing in human microbiomes is the goal as GA initiates a new development project with a leading global pharmaceutical company. The project aims to provide increased standardization and potentially faster clinical decision-making at a low cost by developing GA's proprietary technology diagnostics platform GA-map® for use in a simple microbiome-based rapid PCR test. The collaboration partner is a leading pharmaceutical company with a high focus on gastroenterology. By combining the research and technology of the two companies into a simple microbiome-based rapid PCR test, clinicians will have a tool enabling patient stratification for treatment prescription and monitoring treatment effect.

Ronny Hermansen, CEO of Genetic Analysis, comments:
"We are thrilled to announce our development project for a new microbiome-based rapid PCR test - driving vital change in microbiome diagnostics. This validates our strategy to become the preferred partner for pharmaceutical companies who want to co-develop tests tailormade for their pharma products. The next step will also focus on further exploring the commercial possibilities of a new microbiome-based rapid diagnostic PCR test. I look forward to keeping our investors updated as the project proceeds."

*A companion diagnostic is here to be understood as an in vitro diagnostic (IVD), which provides information for the effective use of a corresponding drug or biological product.